W
W. Schramm
Researcher at Ludwig Maximilian University of Munich
Publications - 5
Citations - 579
W. Schramm is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Haemophilia & Haemophilia A. The author has an hindex of 5, co-authored 5 publications receiving 547 citations.
Papers
More filters
Journal ArticleDOI
Consensus perspectives on prophylactic therapy for haemophilia: summary statement.
Erik Berntorp,Jan Astermark,Sven Björkman,Victor S. Blanchette,Krista Fischer,Paul L. F. Giangrande,Alessandro Gringeri,Rolf Ljung,Marilyn J. Manco-Johnson,Massimo Morfini,Ray F. Kilcoyne,P. Petrini,E. C. Rodriguez-Merchan,W. Schramm,Amy D. Shapiro,H. M. Van Den Berg,Caroline Hart +16 more
TL;DR: Participants in an international conference on prophylactic therapy for severe haemophilia developed a consensus summary of the findings and conclusions of the conference, and agreed upon revised definitions for primary and secondary Prophylaxis and made recommendations concerning the need for an international system of pharmacovigilance.
Journal ArticleDOI
European principles of haemophilia care.
B. T. Colvin,Jan Astermark,Krista Fischer,Alessandro Gringeri,Riitta Lassila,W. Schramm,Angela Thomas,Jørgen Ingerslev +7 more
TL;DR: This document sets out the principles of comprehensive haemophilia care in Europe and the need for education and research programmes for all staff members is emphasized.
Journal ArticleDOI
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
Alessandro Gringeri,Cindy A. Leissinger,Paolo Cortesi,Hyejin Jo,F. Fusco,Silvia Riva,Bülent Antmen,Erik Berntorp,Chiara Biasoli,Shannon L. Carpenter,Kaan Kavakli,Massimo Morfini,Claude Negrier,Angiola Rocino,W. Schramm,Jerzy Windyga,Bulent Zulfikar,Lorenzo G. Mantovani +17 more
TL;DR: By significantly reducing bleeding frequency in good responders, aPCC prophylaxis improved HRQoL compared with on‐demand treatment.
Journal ArticleDOI
Haemophilia care in Europe: the ESCHQoL study.
W. Schramm,Alessandro Gringeri,Rolf Ljung,Karin Berger,Alexander Crispin,Monika Bullinger,Paul L. F. Giangrande,S. von Mackensen,Lorenzo G. Mantovani,László Nemes,Margit Serban +10 more
TL;DR: Statistical analysis revealed that residence in areas with low factor consumption/availability is the most prominent risk factor for joint disease and access of European patients with haemophilia to optimal care with safe factor VIII concentrates is limited and depends on the region of residence.
Journal ArticleDOI
Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity.
Davide Matino,David Lillicrap,Jan Astermark,Gerry Dolan,Craig M. Kessler,Thierry Lambert,Michael Makris,James S. O’Donnell,Steven W. Pipe,Elena Santagostino,Jean Marie Saint-Remy,W. Schramm,Alfonso Iorio +12 more
TL;DR: This review presents the results of a complementary strategy, a Delphi analysis, to add to the considerations of product switching and FVIII immunogenicity.